(Please note the schedule change from previous time listed)
Newormics would like to invite you to a 30 minute live webinar on the applications of the vivoChip® for high-throughput and high-resolution developmental neurotoxicity (DNT) screening, Developmental and Reproductive Toxicity (DART) studies, and germline imaging in 3D. We will demonstrate our results as well as how the vivoChip® can accelerate researchers’ workflow in the lab by enabling immobilization of up to 40 live worms within minutes for high-resolution imaging in any microscope. We will be discussing these areas in detail:
• Germ-line imaging in 3D
• C. elegans for assessing developmental and reproductive toxicity
• Developmental neurotoxicity screening
This webinar would be useful for: researchers in the C. elegans community doing high-resolution imaging or phenotypic scoring of neurons, germline cells, or other tissues; researchers performing chemical library or RNAi screens in multiple populations; toxicologists looking for alternatives to animal models for toxicity testing; and anyone interested in finding out more about our products and services.
We hope to see you there and answer your questions live! Because we understand how busy schedules are, all registrants will have access to the recording of the webinar afterwards
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at Newormics, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities of Newormics. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.